Regulatory filing 📈 Stocks 🌍 United States

Corbus Pharmaceuticals Reports 5% Weight Loss in Phase 1b Obesity Trial

Corbus Pharmaceuticals' oral obesity drug CRB-913 achieved 5.0% weight loss in a 12-week Phase 1b study, with the company now planning regulatory discussions with the FDA.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: CRBP ↑ 7/10 (75% confidence).

📊 Affected Assets (1)

CRBP
Bullish 🤖 75%
📅 Short-term 🌍 US · Explicit

The 8-K discloses Phase 1b CANYON-1 data showing statistically significant weight loss at all doses of CRB-913, with 5.0% LS mean weight loss at 60 mg after 12 weeks (p<0.0001) versus 0.0% on placebo, and an 8.3% discontinuation rate due to adverse events. Positive obesity trial data with a clean safety profile is a direct value driver for a clinical-stage company like Corbus. The 5% magnitude is modest versus injectable GLP-1s, but the oral, non-incretin profile and no plateauing across doses support further development.

Catalysts
  • ▲ Phase 1b data presented at ObesityWeek on November 16, 2026: 5.0% weight loss at 60 mg vs 0.0% placebo, p<0.0001
  • ▲ Discontinuation rate due to AEs of 8.3%, in line with published GLP-1 data
Risk Factors
  • ▼ 5% weight loss at 12 weeks is modest relative to established incretin therapies
  • ▼ Phase 1b trial of 254 participants over 12 weeks; results need confirmation in later-stage trials

🧭 Full analysis of these assets

🎯 Key Takeaways

  • The 60 mg dose of CRB-913 achieved a 5.0% mean weight loss at 12 weeks compared to 0.0% for the placebo group (p<0.0001).
  • The treatment discontinuation rate due to adverse events was 8.3% across all study cohorts.
  • The Phase 1b CANYON-1 trial enrolled 254 obese, non-diabetic adult participants across 15 U.S. sites.
  • Corbus Pharmaceuticals plans to initiate FDA engagement to discuss the data and future development plans for the oral, non-incretin candidate.

📝 Executive Summary

Corbus Pharmaceuticals announced positive Phase 1b CANYON-1 trial results for its oral obesity candidate, CRB-913. The study of 254 participants showed a 5.0% mean weight loss at the 60 mg dose after 12 weeks, with a favorable safety profile and an 8.3% discontinuation rate due to adverse events. The company plans to engage with the FDA to discuss future development paths for the non-incretin therapy.

❓ FAQ

How much weight did patients lose on CRB-913?

In the 12-week Phase 1b CANYON-1 study, the highest 60 mg dose achieved a mean weight loss of 5.0% versus 0.0% on placebo, with all three doses (20 mg, 40 mg, 60 mg) showing statistically significant weight loss. The best individual result was 13.4% weight loss in the 60 mg group.

Was the drug safe?

The company reports CRB-913 was safe and well tolerated: 8.3% of participants discontinued due to adverse events, in line with published GLP-1 data, with no serious or severe psychiatric or gastrointestinal events and only one case of moderate depressive symptoms among 188 treated participants.